# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Vincent van Gogh (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI010-SYN-TD
- Date: 1889-02-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Elise Verhoeven, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review, seen the same day by psychiatry with the coordinated specialty care team. **S**

## History of present illness

Mr. van Gogh returns two weeks after his first visit, four weeks after aripiprazole 10 mg was started in hospital, and is seen by Dr. Feld of the coordinated specialty care team on the same day. He has taken every dose. He has had no confusion and hears nothing by day, but on some nights he still hears his name called as he falls asleep, and on those nights he feels for a while that people in the street are talking about him; by morning he knows this is not so. He sleeps about six hours with breaks. His mood is a little better: he feels less ashamed and has started to sketch, but still cannot paint for long. The passive thoughts that it would be easier not to wake up come less often; he has had no thoughts of suicide or self-harm. He drinks two or three glasses of wine most evenings and no spirits since discharge. He has noticed no restlessness or stiffness. He had his brain MRI and EEG this morning, after a night of shortened sleep as instructed. **S**

| Element | Detail |
|---|---|
| Aripiprazole | 10 mg daily for four weeks, every dose taken |
| Psychotic symptoms | Hears his name called at sleep onset on some nights, with brief suspiciousness; none by day |
| Mood | Somewhat better; PHQ-9 11; item 9 scored 1, less often |
| Sleep | About six hours, broken |
| Alcohol | Two or three glasses of wine most evenings; no spirits |
| Side effects | None noticed |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; appetite normal |
| Neurological | Negative | No restlessness, stiffness, tremor, seizures, or episodes of lost time |
| Ears, nose, mouth, and throat | Negative | Left ear wound healed; hearing unchanged |
| Psychiatric | Positive | Night-time perceptual disturbances at sleep onset; low mood improving; passive thoughts of not waking up less often; no suicidal intent or plan |

4 systems reviewed. **S**

## Current medications

- Aripiprazole 15 mg oral tablet, one tablet by mouth once daily **S**
- Naltrexone 50 mg oral tablet, one tablet by mouth once daily **S**
- Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital) **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 82 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 64.5 kg; BMI 22.3 kg/m². All vital signs are synthetic.

PHQ-9: 11. All results are synthetic.

## Change since baseline

- PHQ-9: 13 at baseline, 11 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 64.5 kg; waist 86 cm; blood pressure 124/78, pulse 82 |
| Head and ears | Left ear wound healed, without infection |
| Neurological | No akathisia, rigidity, tremor, or abnormal movements; AIMS score 0 |
| Psychiatric | Quiet and cooperative; affect constricted but brighter; thought process organized; no hallucinations or delusions elicited today; insight good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **First episode of psychosis with mood features, provisional diagnosis** (F29). Partial response at four weeks: daytime symptoms gone, with residual perceptual disturbances at sleep onset. Intake results support a primary illness rather than a medical cause: urine drug test negative, HIV and syphilis tests nonreactive, TSH 1.8 mIU/L and vitamin B12 388 pg/mL normal. The diagnosis stays provisional. Dr. Feld agrees with a modest dose increase. Safety reviewed: passive thoughts of not waking up less often, no intent or plan; the safety plan and the 988 Suicide & Crisis Lifeline are in his phone; no firearm access. **S**
   - Increase aripiprazole to 15 mg once daily.
   - Enroll in the coordinated specialty care program: care coordinator, therapist, peer specialist, and help returning to work.
   - MRI and EEG results at the next visit.
   - Call the team at once for restlessness after the increase.
2. **Alcohol use disorder** (F10.20). Still drinking two or three glasses most evenings. AST 58, ALT 44 and GGT 96 U/L with MCV 102 fL and PEth 284 ng/mL at intake, consistent with heavy drinking; the liver tests are well below three times the upper limit, and he takes no opioids, so naltrexone is suitable. **S**
   - Start naltrexone 50 mg once daily.
   - Continue thiamine.
   - Liver tests and PEth at the six-week visit.
   - Carry a card saying he takes naltrexone.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg for four weeks with full adherence; partial response; increased to 15 mg |
| Survey | Psychotic and mood symptoms, and early warning signs | Every visit | Completed today | Name called at sleep onset on some nights; brief night-time suspiciousness; none by day |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | No akathisia, parkinsonism, or sedation |
| Examination | Abnormal Involuntary Movement Scale (AIMS) | Baseline, then every 6 months | Completed today | Baseline AIMS score 0, done with the consultation; repeat at six months |
| Examination | Weight and BMI | Every visit for 6 months after starting, then quarterly (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 64.5 kg at four weeks, from 64.0 at intake |
| Examination | Waist circumference | Baseline, then yearly | Completed today | 86 cm. This baseline was due at intake and was taken today instead; nothing was lost because weight was measured at intake. Waist is now part of the visit template |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Up to date | 128/80 at intake; 124/78 today |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Up to date | Fasting glucose 91 mg/dL and A1c 5.3% at intake; next at 12 weeks |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Up to date | Total cholesterol 184, LDL 106, HDL 52, triglycerides 130 mg/dL at intake; next at 12 weeks |
| Laboratory | Prolactin | If symptoms of high prolactin | Not indicated | Aripiprazole rarely raises prolactin; no symptoms |
| Laboratory | Electrocardiogram | Before starting if there are cardiac risk factors or QT-prolonging drugs | Not indicated | No cardiac history, fainting, or QT-prolonging drugs; aripiprazole has little effect on the QT interval |
| Laboratory | First-episode workup (MRI and EEG) | Once, in the first-episode workup | Completed today | Brain MRI and sleep-deprived EEG done this morning; results pending |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 11, from 13; item 9 scored 1 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | Passive thoughts of not waking up less often, no intent or plan; safety plan reviewed; no firearm access; medicines two weeks at a time; the 988 Suicide & Crisis Lifeline in his phone |
| Self-management | Sleep | Every visit | Completed today | About six hours, broken; regular times and less evening coffee agreed |
| Survey | Drinking (AUDIT-C and PEth) | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Up to date | AUDIT-C 9 and PEth 284 ng/mL at intake; two or three glasses most evenings now |
| Medication safety | Naltrexone: liver tests and opioid exposure | Liver tests before starting, then at 1 to 3 months and every 6 to 12 months | Completed today | AST 58, ALT 44 U/L at intake, well below three times the upper limit; urine drug test negative for opioids; naltrexone started |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine 100 mg daily since the hospital |
| Referral | Psychiatry consultation | At the start of treatment for a first episode | Completed today | Seen by Dr. Feld today |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Enrolled today; first meetings with the care coordinator and therapist booked |

## Goal progress

- No return of psychotic symptoms and no readmission through six months, on the lowest effective antipsychotic dose. In progress; target 1889-07-20. **S**
- PHQ-9 score below 5 by six months. In progress; target 1889-07-20. **S**
- Reduce drinking to PEth below 20 ng/mL by six months. In progress; target 1889-07-20. **S**
- Weight gain under 5% and normal glucose, A1c and lipids at the 12-week check. In progress; target 1889-04-20. **S**
- Sleep about seven hours on most nights with regular times by three months. In progress; target 1889-04-20. **S**

## Medication changes

- Stopped: Aripiprazole 10 mg oral tablet, one tablet by mouth once daily (started in hospital) **S**
- Started: Aripiprazole 15 mg oral tablet, one tablet by mouth once daily **S**
- Started: Naltrexone 50 mg oral tablet, one tablet by mouth once daily **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020), American Psychiatric Association (American Journal of Psychiatry)
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018), CANMAT and ISBD (Bipolar Disorders)
- Consensus development conference on antipsychotic drugs and obesity and diabetes (2004), American Diabetes Association, American Psychiatric Association, AACE, and NAASO (Diabetes Care)
- Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026), National Institute of Mental Health
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Six-week visit in four weeks with liver tests, PEth, the PHQ-9, and the MRI and EEG results. Care coordinator by phone weekly. Call at once for restlessness, voices by day, or dark thoughts. **S**
- Next scheduled visit 1889-03-02: six-week review: symptoms, side effects, alcohol, sleep, and test results. **S**
